CD274 and cancer: In cancer types, such as metastatic prostate cancer, where obtaining metastatic tissue biopsy is challenging, our study suggests that serum levels of sMIC may serve as an alternative biomarker to exclude patients who are not likely respond to PD1/PD-L1 blockade treatment.